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httpNitric oxide may inhibit neointimal hyperplasia
by decreasing isopeptidase T levels and activity
in the vasculature
Nick D. Tsihlis, PhD, Muneera R. Kapadia, MD, Ashley K. Vavra, MD, Walker D. Flannery, BA,
Christopher S. Oustwani, BA, Qun Jiang, MD, and Melina R. Kibbe, MD, Chicago, Ill
Objective: Isopeptidase T is a cysteine protease deubiquitinating enzyme that hydrolyzes unanchored polyubiquitin chains
to free monoubiquitin. Nitric oxide (NO) decreases 26S proteasome activity in vascular smooth muscle cells (VSMCs) and
inhibits neointimal hyperplasia in animal models. As NO can cause S-nitrosylation of active-site cysteines, we hypothesize
that NO inhibits isopeptidase T activity through S-nitrosylation. Because accumulation of polyubiquitin chains inhibits
the 26S proteasome, this may be one mechanism through which NO prevents neointimal hyperplasia.
Methods: To investigate our hypothesis, we examined the effect of NO on isopeptidase T activity, levels, and localization in
VSMCs in vitro and in a rat carotid balloon injury model in vivo.
Results: NO inhibited recombinant isopeptidase T activity by 82.8% (t[ 60 minutes, P < .001 vs control). Dithiothreitol
and glutathione (5 mmol/L) both signiﬁcantly reversed NO-mediated inhibition of isopeptidase T activity (P < .001).
NO caused a time-dependent increase in S-nitrosylated isopeptidase T levels in VSMCs, which was reversible with
dithiothreitol, indicating that isopeptidase T undergoes reversible S-nitrosylation on exposure to NO in vitro. Although
NO did not affect isopeptidase T levels or subcellular localization in VSMCs in vitro, it decreased isopeptidase T levels and
increased ubiquitinated proteins after balloon injury in vivo.
Conclusions: Local administration ofNOmay prevent neointimal hyperplasia by inhibiting isopeptidase T levels and activity
in the vasculature, thereby inhibiting the 26S proteasome in VSMCs. These data provide additional mechanistic insights
into the ability of NO to prevent neointimal hyperplasia after vascular interventions. (J Vasc Surg 2013;58:179-86.)
Clinical Relevance: The 26S proteasome is responsible for degrading polyubiquitinated proteins. Isopeptidase T is
a deubiquitinating enzyme that recycles polyubiquitin chains to monoubiquitin. Nitric oxide (NO) decreases formation of
neointimal hyperplasia in animal models and decreases 26S proteasome activity in vascular smooth muscle cells. We
investigated the effects of NO on isopeptidase T and showed that NO inhibits recombinant isopeptidase T activity,
increases S-nitrosylated isopeptidase T levels in vascular smooth muscle cells, and, after balloon injury in vivo, decreases
isopeptidase T levels and increases ubiquitinated proteins. Local administration of NO may prevent neointimal hyper-
plasia by targeting isopeptidase T and inhibiting the 26S proteasome.Nitric oxide (NO) is a known potent inhibitor of neo- previously that external administration of the NO do-
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1-ium-1,2-diolate (PROLI/NO) to the adventitia causes
a 90% decrease in neointimal hyperplasia in a rat carotid
artery balloon injury model.2 Furthermore, we demon-
strated that one mechanism by which NO may inhibit
cell cycle progression is through inhibition of 26S protea-
some catalytic activity,4 which prevents vascular smooth
muscle cell (VSMC) proliferation and, thus, neointimal
hyperplasia. Given that unanchored polyubiquitin chains
are known to inhibit the 26S proteasome,5,6 and isopepti-
dase T is known to hydrolyze predominantly unanchored
polyubiquitin chains into free ubiquitin monomers,5-9
we hypothesized that direct inhibition of isopeptidase T
may be another mechanism by which NO inhibits
VSMC proliferation. Furthermore, it is possible that NO
may prevent protein breakdown by affecting the activity
of isopeptidase T through S-nitrosylation of active site
cysteines.179
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ubiquitin-proteasome pathway. A protein targeted for
destruction is marked by ligation of a polyubiquitin strand,
which is recognized and removed by the 26S protea-
some.10 Polyubiquitin chains are formed by ﬁrst linking
ubiquitin via a peptide bond from its C-terminal glycine
(G76) to the ε-amino group of a lysine on the target
protein.7 Subsequent ubiquitins are added to the chain
by conjugation to G76 through an isopeptide bond to
lysine 48 (K48), which marks the protein for proteasomal
degradation.11 As there are seven lysines in ubiquitin,
several polyubiquitin linkages, including monoubiquitina-
tion, that have other functions in eukaryotic cells are
possible (see reviews).12,13 Here, we focus on K48-linked
polyubiquitin chains, which are the preferred substrate for
isopeptidase T, are sufﬁcient to send tagged proteins to
the 26S proteasome for destruction,14 and are the principal
signal for proteasomal degradation in cells.15
Although isopeptidase T can bind several ubiquitin
conﬁgurations, it has great afﬁnity for unanchored polyubi-
quitin chains.6,16 Thus, isopeptidase T functions not only
to recycle ubiquitin for reuse by ubiquitin enzymes, but
also to promote proper function of the 26S proteasome.
Although much is known about the mechanism of isopep-
tidase T activity in vitro, little is known about its activity in
the vasculature. Nor is much known about how NO, an
important molecule constitutively expressed in the vascula-
ture, affects isopeptidase T activity. To investigate our
hypothesis, the aim of this study was to evaluate the effect
of exogenous NO on isopeptidase T activity and levels in
the vasculature in vitro and in vivo.
METHODS
Isopeptidase T activity assay. Human recombinant
isopeptidase T (5 nmol/L; Boston Biochem, Cambridge,
Mass) was combined with reaction buffer (100 mmol/L 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES],
pH7.8, 1mmol/LEDTA, 2mmol/L dithiothreitol [DTT],
0.2 mg/mL bovine serum albumin [BSA; Sigma, St. Louis,
Mo]). Next, the ﬂuorogenic peptide substrate ubiquitin-
AMC (0.5 mmol/L [Boston Biochem] in 50 mmol/L
HEPES, 150 mmol/L NaCl, 1 mmol/L DTT, pH 8.0) was
added to each treatment group. The ﬁnal reaction volume
was 100 mL. Isopeptidase T activity, determined by cleavage
of the ﬂuorescent substrate, was measured over 60 minutes
using an excitation wavelength of 380 nm and an emission
wavelength of 460 nm.
Cell culture. The previously described explant method
was used to culture VSMCs from the abdominal aortas of
male C57BL/6J mice (Jackson Laboratory; Bar Harbor,
Me).17,18 Cells were maintained, and their purity was
assessed, as previously described.19
Western blot analysis. VSMCs (0.5  106/plate) in
10-cm dishes were treated for 24 hours in the presence
or absence of the S-nitrosothiol NO donor S-nitroso-
N-acetylpenicillamine (SNAP). Cells were collected,
protein concentration was determined, and proteins were
subjected to sodium dodecyl sulfate-polyacrylamide gelelectrophoresis (SDS-PAGE) and transfer as previously
described.19 Membranes were incubated with USP5 anti-
body (AP2134b; Abgent, San Diego, Calif) diluted 1:1000
in 5% BSA or ubiquitin antibody (Boston Biochem) diluted
1:1000 in 1 phosphate-buffered saline (PBS). Proteins
were visualized and equal loading was veriﬁed as previously
described.19 b-actin expression was used to normalize
quantitations of isopeptidase T levels (ImageJ; National
Institutes of Health, Bethesda, Md). Recombinant human
isopeptidase T (E-322; Boston Biochem) was loaded as
a positive control.
Biotin switch assay. VSMCs (0.8  106/plate) were
treated with or without SNAP (500 mmol/L) for 2, 4, or 6
hours. For groups treated with DTT and SNAP, 5 mmol/
L DTT was added 30 minutes before SNAP. Cells were
washed with 3 mL cold 1 PBS, scraped in lysis buffer (50
mmol/L Tris, pH 7.5, 150 mmol/L NaCl, 0.5%
deoxycholic acid, 0.1% SDS, 1% Nonidet P-40, 0.1 mmol/
L neocuproine, and protease cocktail; Pierce, Rockford,
Ill), incubated on ice for 30 minutes, and pelleted at 4C.
Protein concentration of the supernatant was measured
by bicinchoninic acid (BCA) assay (Pierce). Blocking
buffer—2.5% SDS and 20mmol/Lmethyl methanethiosul-
fonate (MMTS) in HEN buffer (250 mmol/L HEPES-
NaOH, pH 7.7, 1 mmol/L ethylenediaminetetra-acetic
acid [EDTA], 0.1 mmol/L neocuproine)—was added
to 500mg of protein and incubated at 50C for 20minutes to
block free thiol groups. MMTS was removed by addition of
cold acetone and centrifugation, followed by resuspension of
the pellet in HENS buffer (HEN plus 1% SDS).
Nitrosothiols were labeled by incubation in labeling
solution (50 mmol/L biotin-HPDP (N-[6-(biotinamido)
hexyl] 30-(20-pyridyldithio)propionamide; Pierce) in dime-
thylformamide dissolved to 4mmol/L in dimethylsulfoxide)
and ascorbate solution (50 mmol/L sodium ascorbate in
water) for 1 hour at 25C. Biotin-HPDP was removed by
addition of cold acetone (20C) for 20 minutes, followed
by centrifugation. This was repeated to completely remove
biotin-HPDP. After resuspension in HENS buffer, neutrali-
zation buffer (20 mmol/L HEPES-NaOH, pH 7.7, 100
mmol/L NaCl, 1 mmol/L EDTA, and 0.5% Triton X-100
in water) was added, followed by incubation with
streptavidin-agarose beads for 1 hour at room temperature.
After ﬁve washes with neutralization buffer plus 600
mmol/L NaCl, with beads pelleted after each wash, bound
biotinylated proteins were recovered by incubation for 20
minutes on ice in elution buffer (20 mmol/L HEPES-
NaOH, pH 7.7, 100 mmol/L NaCl, 1 mmol/L EDTA,
and 100 mmol/L 2-mercaptoethanol in water). Beads were
resuspended in 3 SDS-PAGE sample buffer, boiled for 5
minutes at 100C, and stored at 80C until SDS-PAGE
and Western blot analysis.
Animal surgery. Animal procedures were all approved
by the Institutional Animal Care and Use Committee of
Northwestern University and performed in accordance
with National Institutes of Health guidelines outlined in
the Guide for the Care and Use of Laboratory Animals
(Publication 85-23, 1996). Surgeries were performed as
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ing between 350 and 400 g.19 Rats anesthetized with
inhaled isoﬂurane (0.5-3%) were given subcutaneous
atropine (0.1 mg/kg) to decrease airway secretions. A
midline neck incision allowed for dissection of the left
common, external, and internal carotid arteries. Microclips
were used to obtain proximal and distal control. A trans-
verse arteriotomy on the external carotid allowed for
insertion of a 2F Fogarty catheter (generously provided by
Edwards Lifesciences) into the common carotid, which was
injured by inﬂating the balloon for 5 minutes (5 atm). The
balloon was removed, the external carotid ligated, and ﬂow
restored as previously described.19 After injury, the NO
donor PROLI/NO was applied as a powder on the
external adventitial surface of the injured common carotid
artery as previously described.19 Controls included injury
alone and no injury (n ¼ 3/group).
Histological tissue processing. Carotid arteries har-
vested 3 or 14 days after balloon injury were frozen and
cut into sections (5 mm) as previously described.19 The
injuryþNOgroup was treated with 10mg of PROLI/NO.
Lysate tissue processing. Three days after balloon
injury, carotid arteries were harvested and homogenized
as previously described.19 After a BCA assay to determine
protein concentration, samples were held at 80C until
analysis by SDS-PAGE and Western blotting. The injury þ
NO group was treated with 20 mg PROLI/NO.
Immunoﬂuorescence staining. VSMC (1 x 104 cells/
well) grown on glass coverslips (VWR International, West
Chester, Penn) in 24-well plates were exposed to
medium 6 SNAP for 24 hours. Cells ﬁxed with 10%
buffered formalin (Fisher Scientiﬁc, Fair Lawn, NJ) were
permeabilized with 0.3% Triton X-100 in PBS (Fisher
Scientiﬁc). Next, cells were blocked in 5% BSA or donkey
serum (Sigma) diluted 1:20 in 0.5% BSA. Cells were
incubated in USP5 antibody (sc-79811; Santa Cruz
Biotechnology, Santa Cruz, Calif) diluted 1:500 in 0.5%
BSA, followed by donkey anti-goat AlexaFluor 555 (Invi-
trogen) diluted 1:3000 in PBS. Negative controls were
incubated without primary antibody. 40,6-Diamidino-
2-phenylindole (DAPI, 60 nmol/L; Invitrogen) was used
to stain nuclei. Coverslips were adhered to slides using
ProLong Gold Antifade Reagent (Invitrogen), and digital
images acquired on a Zeiss Imager.A2 microscope (Hall-
bergmoos, Germany) using the 20 objective.
Carotid artery sections from uninjured rats, injured rats,
and rats subjected to injury þ NO were ﬁxed with parafor-
maldehyde (2%), then permeabilized in Triton X-100
(0.3% in PBS). After being blocked in 5% BSA, sections
were incubated with USP5 antibody (1:100 in BSA; Santa
Cruz Biotechnology). Negative controls were incubated
without primary antibody. After incubation with donkey
anti-goat AlexaFluor 555 antibody (1:1000 in PBS; Invitro-
gen), 60 nmol/L DAPI was used to stain nuclei, and slides
were coverslipped as above. Digital images were acquired as
above, except using the 10 objective.
Statistical analysis. Numerical results are given
as means 6 the standard errors of the mean. SigmaStat(SPSS, Chicago, Ill) was used to perform one-way anal-
ysis of variance (ANOVA) on differences between groups,
and all pairwise comparisons were assessed with the
Student-Newmann-Keuls post hoc test. P < .05 was used
to indicate statistical signiﬁcance.
RESULTS
NO inhibits isopeptidase T activity in a concentration-
dependent manner. To evaluate isopeptidase T activity
in vitro, an assay was performed using recombinant isopep-
tidase T enzyme 6 SNAP (125-1000 mmol/L). Baseline
activity for isopeptidase T at 60 minutes was 1001 6 16
s1. Increasing concentrations of SNAP led to signiﬁcantly
increased inhibition of isopeptidase T activity (P < .001 at
SNAP $ 500 mmol/L) (Fig 1, A). SNAP (1000 mmol/L)
inhibited isopeptidase T activity by 82.8% after 60 minutes.
The parent compound NAP (1000 mmol/L), used as
a negative control, only slightly inhibited isopeptidase T
activity (17%, P < .02) compared with baseline. A kinetics
assay showed that isopeptidase T activity plateaued after 60
minutes, and SNAP concentrations above 250 mmol/L
signiﬁcantly inhibited isopeptidase T activity (Fig 1, B).
Dithiothreitol and glutathione prevent the inhibi-
tion of isopeptidase T activity by NO. To determine if
NO inhibits isopeptidase T activity via modiﬁcation of
cysteine thiol groups, DTT (5 mmol/L) was added to
the activity assay before SNAP (1000 mmol/L). DTT
signiﬁcantly prevented SNAP-mediated inhibition of iso-
peptidase T activity, restoring activity to 77.8% of control
(*P < .001 vs control; **P < .001 vs SNAP) (Fig 2). To
further investigate the speciﬁcity of this interaction, gluta-
thione (GSH, 5 mmol/L) was added to the activity assay
before SNAP (1000 mmol/L). GSH signiﬁcantly prevented
inhibition of isopeptidase T activity mediated by SNAP,
with activity levels observed at 77.8% of control (*P < .001
vs control; **P < .001 vs SNAP) (Fig 2). Neither reducing
agent alone signiﬁcantly affected isopeptidase T activity.
Thus, isopeptidase T activity appears susceptible to regu-
lation via modiﬁcation of thiol groups.
NO causes S-nitrosylation of isopeptidase T in
a time-dependent manner. Because isopeptidase T activity
was affected by reducing agents, we sought to ascertain
whether NO S-nitrosylates isopeptidase T. A biotin switch
assay was performed after treatment of VSMCs with SNAP
(500 mmol/L) 6 DTT (5 mmol/L) for 2, 4, or 6 hours.
As shown in Fig 3, longer SNAP (500 mmol/L) exposure
times caused elevated levels of S-nitrosylated isopeptidase
T (SNO-IsoT), seen most prominently at 4 hours. Though
levels of SNO-IsoT decreased by 6 hours (not shown),
this action of NO was prevented at all time points by
addition of 5 mmol/L DTT.
NO does not affect isopeptidase T levels or
intracellular localization in VSMCs. The effect of NOon
isopeptidase T levels was assessed byWestern blot analysis of
VSMCs exposed to SNAP (125-1000 mmol/L) for
24 hours. No effect of NO on isopeptidase T levels was
observed by densitometry analysis of Western blots (Fig 4,
A). Of note, the antibody used recognized two isopeptidase
Fig 2. Nitric oxide (NO)-mediated inhibition of isopeptidase
T activity is prevented by reducing agents. Isopeptidase T activity
was assessed with S-nitroso-N-acetylpenicillamine (SNAP, 1000
mmol/L) 6 dithiothreitol (DTT, 5 mmol/L) or glutathione
(GSH, 5 mmol/L). t ¼ 60 minutes, n ¼ 3 per each treatment
group. Data are representative of four separate experiments.
*P < .001 vs control, yP < .001 vs SNAP.
Fig 1. Nitric oxide (NO) inhibits isopeptidase T activity. Iso-
peptidase T activity was assayed with and without S-nitroso-N-ace-
tylpenicillamine (SNAP) (A) at 60 minutes and (B) every 5 minutes
for 60 minutes. N-acetylpenicillamine (NAP, 1000 mmol/L) is
a negative control. n ¼ 3 per treatment group. Data are represen-
tative of four separate experiments. *P< .001 vs control, **P< .02
vs control.
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bottom band, as this is themost prominent band observed in
the recombinant isopeptidase T (rIsoT) lane (Fig 4, A). To
determine whether NO exposure inﬂuenced localization of
isopeptidase T within the cell, immunoﬂuorescence staining
for isopeptidase T was performed in VSMC 6 SNAP
(1000 mmol/L, 24 hours). Isopeptidase T was located
mostly in the cytoplasm (Fig 4, B), and addition of NO did
not affect intracellular localization of isopeptidase T.
NO decreases isopeptidase T levels in vivo.
Although NO had no effect on isopeptidase T levels in
VSMC in vitro, because there are many cell types in the
arterial wall before and after injury, we wanted to investi-
gate whether NO affected isopeptidase T levels in vivo.
After injury, carotid arteries from male Sprague-Dawley
rats were treated with or without 10 mg PROLI/NO,
removed at 3 or 14 days, sectioned, and immunoﬂuo-
rescence stained for isopeptidase T. We observed anincrease in isopeptidase T levels throughout the arterial
wall at both time points after injury, with the biggest
increase at 3 days observed in the adventitia and the
biggest increase at 14 days seen in the neointima (Fig 5,
A). Although NO decreased the overall levels of iso-
peptidase T throughout the arterial wall at both time
points after injury, the most prominent decrease was seen
at 14 days.
To further assess isopeptidase T in our animal model,
balloon-injured carotid arteries treated with or without
20 mg PROLI/NO were harvested at 3 days, homoge-
nized, and analyzed by Western blotting for isopeptidase
T or ubiquitinated protein levels. As seen in Fig 5, B,
although there was a decrease in isopeptidase T expression
after balloon injury, there was a marked decrease in isopep-
tidase T levels in the injury þ NO vessels. Additionally, we
observed an increase in ubiquitinated proteins in the
injury þ NO group which corresponded with decreases
in free ubiquitin and isopeptidase T (Fig 5, B). Of note,
the data in Fig 5, B, represent all cells present throughout
the arterial wall.
DISCUSSION
We demonstrate here that NO inhibits the activity, but
not levels, of isopeptidase T in VSMC in vitro, while
decreasing its levels and increasing ubiquitinated proteins
in the vasculature in vivo. This correlation between the
effect of NO on isopeptidase T activity and the presence
of S-nitrosylated isopeptidase T is further strengthened by
evidence that NO inhibits isopeptidase T activity in
a concentration-dependent fashion in vitro. S-Nitrosylation
is likely responsible for mediating this effect, which is
reversed by reducing agents. Immunoﬂuorescent staining
and Western blot analysis of VSMC in vitro illustrate that
NO had no effect on the levels or intracellular location of
isopeptidase T at short or long time points. Finally, we
Fig 3. Nitric oxide (NO) causes S-nitrosylation of isopeptidase
T (SNO-IsoT) in a time-dependent manner. After treatment
of vascular smooth muscle cells (VSMCs) with S-nitroso-N-ace-
tylpenicillamine (SNAP, 500 mmol/L) 6 dithiothreitol (DTT, 5
mmol/L) for the times indicated, SNO-isopeptidase T was
enriched from cell lysates via biotin switch assay, then subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blot analysis. Data are representative of three
separate experiments.
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levels of isopeptidase T in an animal model of neointimal
hyperplasia, which correlates with increased ubiquitinated
protein levels.
Althoughmuch is known about the biochemistry, struc-
ture, function, and mechanism of isopeptidase T, little is
known about its role in the vasculature. Decreased isopepti-
dase T function can lead to accumulation of ubiquitinated
proteins in cardiac myocytes, which can cause cell death
and heart failure in humans.22 Kostin et al observed twofold
increases in ubiquitin mRNA and ubiquitin-conjugating
(E2) enzyme levels and a twofold reduction in isopeptidase
T expression in failing human hearts.22 Chronic proteasomal
inhibition also contributes to development of coronary
atherosclerosis.23 Herrmann et al observed reductions
in vasorelaxation, increased intima-to-media ratios, and
increased oxidative stress in female pigs fed a high-
cholesterol diet and given MLN-273 (a proteasome inhib-
itor).23 Interestingly, localized proteasomal inhibition was
also linked to decreased development of restenosis in
a rat carotid artery balloon injury model.24 Meiners et al
administered the proteasome inhibitor MG132 for 5
minutes at the site of injury and saw decreased inﬂammation,
increased apoptosis, and decreased intima-to-media area
ratios up to 14 days after treatment.24 Neointimal hyper-
plasia has also been linked to proteasome activity. Farieset al stained biopsy specimens of atherosclerotic and normal
vessels, as well as patent and occluded grafts, for 11S protea-
some activator (PA28) expression and observed that areas of
vessels with less PA28 staining (lower proteasome activity)
had increased levels of atherosclerosis and neointimal hyper-
plasia.25 Finally, Stone et al observed reduced expression of
ubiquitin, E2 enzymes, ubiquitin ligase enzymes, and pro-
teasomal subunits at the anastomoses of vein grafts in the
carotid arteries of mongrel dogs.26 Although increased
ubiquitinated protein levels were described in some of
these studies, and proteasome activity reductions were
described in all of them, only Kostin et al speciﬁcally inves-
tigated isopeptidase T, and their study did not address iso-
peptidase T in blood vessels.22 Thus, although these
studies make clear that 26S proteasome activity is linked
to neointimal hyperplasia, much remains unknown about
isopeptidase T in the vasculature. The work presented
here adds valuable information to a nascent ﬁeld of prom-
ising research.
We show, for the ﬁrst time, that NO inhibits isopepti-
dase T activity in the vasculature, most likely by S-nitrosy-
lation of a critical cysteine residue, a common mechanism
by which NO regulates the activity of cysteine proteases.27
Previous work in our laboratory established that NO
donors applied to the external surface of the rat carotid
artery after balloon angioplasty result in signiﬁcant inhibi-
tion of neointimal hyperplasia in several different animal
models.2,3,28 Because we have used the same NO donor
and amounts in this work, our data should be directly
translatable. Thus, inhibiting isopeptidase T activity may
allow unanchored polyubiquitin chains to accumulate
and inhibit the 26S proteasome, resulting in the buildup
of cell cycle proteins, ultimately leading to less prolifera-
tion, and less neointima formation. In support of this
theory, NO is known to increase expression of cell cycle
inhibitors like p21 and p27, as well as p53, and these
increases are associated with inhibition of neointimal
hyperplasia.17,29 Further, Dayal et al reported that isopep-
tidase T inhibition causes both p53 activation and unan-
chored polyubiquitin chain accumulation.8 Our current
data also indicate a buildup of ubiquitinated proteins,
and a concomitant loss of free ubiquitin, in the injury þ
NO treatment group. Thus, a causal link has been estab-
lished between isopeptidase T activity and neointimal
hyperplasia. Indeed, because NO affects such a varied
number of cell cycle proteins and cyclin-dependent kinases,
it makes sense that NO is acting on a central regulator,
such as the ubiquitin-proteasome pathway, to exert these
effects.
Although our data reveal a number of new discoveries
about the actions of isopeptidase T in the vasculature and
the relationship between NO and isopeptidase T, there
are limitations to this study. For instance, we did not assess
levels of SNO-isopeptidase T in balloon-injured vessels
because of the limitations in currently available reagents
speciﬁc to isopeptidase T or SNO-isopeptidase T. On the
basis of previous studies, we would expect levels of SNO-
isopeptidase T in NO-treated balloon-injured vessels to
Fig 4. Nitric oxide (NO) does not affect isopeptidase T (isoT) levels or intracellular localization in vascular smooth
muscle cells (VSMCs). A, Western blot analysis of isopeptidase T levels in VSMC exposed to S-nitroso-N-acetylpe-
nicillamine (SNAP, 125-1000 mmol/L) for 24 hours showed no effect of NO. B, Immunoﬂuorescence staining
performed on VSMC for isopeptidase T (red) after exposure to SNAP (1000 mmol/L) for 24 hours showed mostly
cytoplasmic staining and no change in levels or localization with NO. Blue represents nuclei stained with 40,6-
diamidino-2-phenylindole. Data and images are representative of at least two separate experiments. rIsoT, Recombi-
nant isopeptidase T.
JOURNAL OF VASCULAR SURGERY
184 Tsihlis et al July 2013increase relative to both injury alone and uninjured vessels.
Another limitation is that we did not directly assess isopep-
tidase T activity in VSMC or carotid artery lysates. These
studies are challenging because of the abundance of deubi-
quitinating enzymes present in cells and the lack of reagents
speciﬁc to isopeptidase T. We expect that these experi-
ments would indicate that NO decreases isopeptidase
T activity in vivo, which would lead to ubiquitin-
proteasome pathway inhibition as a result of accumulation
of proteins with unprocessed K48-linked polyubiquitin
chains. We also did not stain carotid artery sections for
the presence of SNO-isopeptidase T because of reagent
limitations, but would expect it would increase in NO-
treated vessels. As this ﬁeld of research expands, new
reagents will become available, allowing for these addi-
tional studies in the future.
Lastly, to shed light on the possible involvement of
other cells in the vessel wall, we performed immunoﬂuores-
cence staining for isopeptidase T on NIH-3T3 ﬁbroblasts
and primary rat VSMC. We observed no changes in either
the levels of isopeptidase T or its subcellular localization inany of the cell types, or at any of the SNAP concentrations
(125-1000 mmol/L), tested (data not shown). Because
several other cell types are present in the arterial wall,
including endothelial cells, macrophages, leukocytes, and
stem cells, it is possible that some of these other cell types
may be the cells in which NO has its effect. Furthermore,
simple in vitro cell culture models cannot accurately mimic
the environment in the arterial wall after injury. Thus, we
are not surprised that we did not detect differences in the
two cell types we evaluated in vitro.
In summary, we demonstrate a strong correlation
between the time- and concentration-dependent inhibitory
effects of NO on isopeptidase T activity in vascular cells and
the presence of SNO-isopeptidase T in these cells. We also
show a correlation between decreased isopeptidase T levels
in the vasculature after administration of NO and a de-
crease in neointimal hyperplasia formation, which may be
achieved via the formation of SNO-isopeptidase T. This
effect on isopeptidase T activity can be prevented in cells
by reducing agents, which prevent the formation of SNO
on isopeptidase T. We provide evidence that, although
Fig 5. Nitric oxide (NO) decreases levels of isopeptidase T (isoT) and free ubiquitin in vivo, with a concomitant increase
in ubiquitinated proteins. A, Immunoﬂuorescence staining for isopeptidase T (red) performed on balloon-injured rat
carotid arteries treated with and without 10 mg PROLI/NO for 3 or 14 days showed that isopeptidase T increased after
injury and decreased with NO. Nuclei are shown in blue (4’,6-diamidino-2-phenylindole), and internal elastic lamina
autoﬂuorescence is visible in green. The negative control (ie, no primary antibody) revealed no red staining. Data are
representative of two separate stains. B, Western blot analysis performed on balloon-injured rat carotid artery lysates
treated with and without 20 mg PROLI/NO for 3 days showed a signiﬁcant decrease in isopeptidase T levels (left) in the
injury þ NO group. Free ubiquitin levels also decreased, with a concomitant increase in ubiquitinated proteins (right)
observed in the injury þ NO group. rIsoT, Recombinant isopeptidase T. *P < .03 vs control. n ¼ 3/group.
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Volume 58, Number 1 Tsihlis et al 185administration of NO in vitro had no effect on isopeptidase
T levels or intracellular localization in VSMC, external
administration of NO in vivo in a carotid artery model of
neointimal hyperplasia decreased isopeptidase T levels,
while increasing levels of ubiquitinated proteins. We
conclude that local administration of NO may preventthe formation of neointimal hyperplasia by inhibiting iso-
peptidase T activity via S-nitrosylation, resulting in accu-
mulation of unanchored polyubiquitin chains and further
inhibiting the 26S proteasome. As others have shown,
the ubiquitin-proteasome pathway is a rich vein that can
be mined for therapeutic interventions for a number of
JOURNAL OF VASCULAR SURGERY
186 Tsihlis et al July 2013diseases. The data we present here add one more ﬁne-scale
tool that may be useful in preventing restenosis after
vascular interventions.
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